|
| Antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions. In this webinar, we discuss the latest in library synthesis technology, and its use to build innovative libraries that harness structural and developability features to cover a wide range of antibody drug targets. We show how these libraries enable the discovery of high-affinity drug-like antibodies, often without the need for affinity maturation.
Save Your Spot
We also discuss the use of these high-quality libraries to develop antibodies targeting hard-to-drug target classes like GPCRs, ion channels, and carbohydrates. |
|
|
|
|
